Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 3/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | DRD5 | P21918 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | SMO | Q99835 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031812 | 0.87 | DRD4 (1.00) | DRD4DRD2DRD3SIGMAR1KDM4E | |
| SCHEMBL8725812 | 0.87 | SIGMAR1 (0.75) | GAAL3MBTL1SIGMAR1POLBKDM4E | |
| SCHEMBL15937936 | 0.87 | DRD4 (0.67) | DRD4GAAL3MBTL1MAPTDRD2 | |
| SCHEMBL2462363 | 0.86 | L3MBTL1 (1.00) | DRD4GAAL3MBTL1MAPTDRD2 | |
| SCHEMBL6031666 | 0.85 | MAPT (1.00) | DRD4GAAL3MBTL1MAPTDRD2 | |
| SCHEMBL5988539 | 0.85 | MAPT (0.77) | DRD4GAAL3MBTL1MAPTDRD2 | |
| SCHEMBL6794331 | 0.84 | DRD4 (0.79) | DRD4GAAL3MBTL1DRD2DRD3 | |
| SCHEMBL588149 | 0.84 | DRD4 (1.00) | DRD4GAAL3MBTL1MAPTDRD2 | |
| SCHEMBL7977889 | 0.83 | HTR1A (0.78) | MAPTDRD2DRD3SIGMAR1DRD5 | |
| Bromide SCHEMBL6030792 | 0.83 | MAPT (0.97) | DRD4GAAL3MBTL1MAPTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | DRD4 3838/4885GAA 364/4885L3MBTL1 2703/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | DRD4 3838/4885GAA 364/4885L3MBTL1 2703/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | DRD4 3838/4885GAA 364/4885L3MBTL1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.